Global Research Associates LLC — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$99,227	7
2024	Research	$1,055,797	34
2023	Research	$136,203	4

Breakdown

Who paid Research payments · program years 2023–2025

Mylan Inc. $478,322 17 payments
Braintree Laboratories, Inc. $416,299 13 payments
Exeltis, USA Inc. $367,106 14 payments
Amgen Inc. $29,500 1 payment

Studies the money was for Research payments · program years 2023–2025

Mr-100A-01-Td-3001-A Phase 3, Multicenter, Open-Label, Single Arm Study of Mr-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety $478,322 17 payments
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease $416,299 13 payments
Cf13303 $297,379 8 payments
Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females $69,727 6 payments
A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) $29,500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.